ArticleThe journal of vascular access2026
Vessel preparation with FLEX Vessel Prep device prior to paclitaxel-coated angioplasty improves outcomes of hemodialysis vascular access.
Article in The journal of vascular access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLong-term vascular access (VA) is critical for patients with kidney disease or hyperlipoproteinemia, yet stenotic lesions often compromise its patency, necessitating frequent interventions. This study compares the efficacy of three endovascular treatment modalities-plain old balloon angioplasty with drug-coated balloon (POBA+DCB), scoring balloon with drug-coated balloon (SB+DCB), and FLEX vessel preparation with drug-coated balloon (VP+DCB)-in the treatment of VA stenoses. MATERIALS AND
methodsA retrospective analysis was conducted on 175 VA interventions performed between June 2022 and October 2024 at a dedicated VA center. Patients were divided into three groups based on treatment modality: POBA+DCB (
resultsReinterventions per patient-year were significantly lower in the VP group (0.372) compared to POBA (0.695) and SB (0.917) (
conclusionsThese findings suggest that VP+DCB may provide superior patency and reduced reintervention rates compared to POBA+DCB and SB+DCB, offering a promising alternative for the management of VA-stenoses in real-world clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.